Biology of Manual Therapies (R21) | Apply Online

Frequently Asked Questions (FAQs): Biology of Manual Therapies (R21) - PA-10-210

1) What is the NIH funding opportunity "Biology of Manual Therapies (R21)" (PA-10-210)?

PA-10-210 was an NIH funding opportunity announcement (FOA) that supported exploratory research to understand the basic biology and mechanisms underlying manual therapy approaches. It emphasized mechanistic studies explaining how manual interventions may produce physiological effects.

2) What is the main goal of this FOA?

The central goal was to uncover mechanisms of action for manual therapies, rather than to evaluate whether these therapies "work" in a broad clinical effectiveness sense. The FOA sought studies that could explain observed effects through measurable biological pathways.

3) Which NIH components issued this announcement?

The announcement was issued jointly by the National Center for Complementary and Alternative Medicine (NCCAM, now known as the National Center for Complementary and Integrative Health, NCCIH) and the National Cancer Institute (NCI).

4) What types of manual therapies were specifically mentioned?

The FOA encouraged research on interventions such as spinal manipulation, mobilization, and massage therapy.

5) What kinds of biological effects or systems were investigators encouraged to study?

Investigators were encouraged to examine biomechanical, immunological, endocrinological, and neurophysiological consequences of manual therapy interventions. This included studying how touch-based forces might influence tissues and joints, nervous system signaling, immune activity or inflammation, and hormone or stress-response pathways.

6) Does this FOA focus on clinical outcomes or mechanism of action?

The focus is on mechanism of action. The FOA emphasized understanding how and why manual therapies may lead to physiological changes, rather than broadly testing clinical efficacy.

7) What is the funding mechanism used in PA-10-210?

This FOA used the NIH R21 mechanism, which is commonly intended for early-stage, exploratory, or high-risk/high-reward research.

8) Why is the R21 mechanism a good fit for this topic?

Because mechanistic questions often require proof-of-concept work, method development, or testing novel hypotheses, the R21 structure supported teams aiming to generate foundational data without the level of preliminary evidence typically expected for larger R01 projects.

9) Was there a companion funding opportunity for larger or more developed projects?

Yes. PA-10-210 ran in parallel with a companion announcement, PA-10-209, which supported the same scientific scope using the R01 mechanism.

10) What types of projects would have been a strong match for this FOA (based on the description)?

Projects aligned with this FOA included exploratory mechanistic studies that: (a) establish proof-of-concept biological findings; (b) refine measurement approaches such as physiological biomarkers or imaging-based endpoints; or (c) clarify biological pathways that could support later clinical or translational research.

11) What was the award ceiling listed for this opportunity?

The FOA listed an award ceiling of $200,000.

12) Were award size and project duration fixed or variable?

Award size and project duration were expected to vary depending on the proposed aims, study design, and the resources required.

13) How many awards were expected to be made?

The FOA indicated that the total number of awards and total dollars committed would depend on factors such as the number of applications received, their scientific quality, and their proposed budgets and timelines.

14) Was cost sharing or matching required?

No. The FOA stated there was no cost sharing or matching requirement.

15) Who was eligible to apply?

Eligibility was broad and included many U.S. and non-U.S. organization types, including: public and private institutions of higher education; nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) entities); for-profit organizations (including small businesses); and a wide range of government entities (state, county, city/township, special district, and independent school districts), as well as public housing authorities/Indian housing authorities.

16) Were foreign (non-U.S.) organizations eligible?

Yes. Foreign (non-U.S.) entities were explicitly listed as eligible applicants.

17) Were organizations such as HBCUs, HSIs, tribal organizations, and U.S. territories included in eligibility?

Yes. The FOA explicitly included institution types and groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), tribal organizations and tribal governments (including federally recognized tribes), faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

18) What were the open and close dates for this FOA?

The FOA was posted/created on May 27, 2010. It remained open until its final closing date of January 7, 2014, and it had an archive date of February 7, 2014.

19) What CFDA numbers were associated with this opportunity?

The opportunity was associated with CFDA 93.213 (Research and Training in Complementary and Integrative Health) and CFDA 93.395 (Cancer Treatment Research).

20) How was this opportunity categorized in terms of funding type and activity area?

It was categorized as a discretionary grant opportunity within education and health-related funding activity areas.

21) What role did cancer-related research play in this FOA?

Because NCI co-issued the FOA, the scope included contexts relevant to cancer and symptom management, such as investigating how manual therapies might influence biological pathways related to symptoms or physiological responses in cancer care settings.

22) What kinds of endpoints or measurements were highlighted as relevant (based on the description)?

The FOA description suggests interest in measurable mechanistic endpoints such as physiological biomarkers and imaging-based endpoints, as well as indicators tied to nervous system signaling, immune activity/inflammation, and endocrine or stress-response pathways.

23) Who was listed as the contact for questions?

The provided contact support in the description was technical in nature: the NIH Office of Extramural Research (OER) offered support for access and linking issues through its webmaster email, rather than listing a programmatic scientific contact in the provided text.

24) What was the broader purpose of this FOA for the field of manual therapies?

The FOA aimed to strengthen the scientific foundation for manual therapies by moving beyond descriptive outcomes toward measurable, testable biological models. The intent was to clarify how and why interventions like manipulation and massage produce physiological changes and to generate mechanistic evidence that could inform future clinical research and therapy optimization.

25) How does PA-10-210 relate to future clinical or translational research?

By funding mechanistic and proof-of-concept studies, PA-10-210 was positioned to generate foundational data and validated approaches that could later justify broader clinical or translational studies, including work to refine protocols or identify contexts where manual therapies may be most relevant.